4.8 Article

Hepcidin Regulation in Prostate and Its Disruption in Prostate Cancer

期刊

CANCER RESEARCH
卷 75, 期 11, 页码 2254-2263

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-14-2465

关键词

-

类别

资金

  1. NIH [R01 CA-171101, R01 CA188025, RO1 DK-069533, RO1 DK-071837, RO1-DK087727]
  2. Howard Goodman Fellowship Award from the Massachusetts General Hospital

向作者/读者索取更多资源

Hepcidin is a circulating peptide hormone made by the liver that is a central regulator of systemic iron uptake and recycling. Here, we report that prostate epithelial cells also synthesize hepcidin, and that synthesis and secretion of hepcidin are markedly increased in prostate cancer cells and tissue. Prostatic hepcidin functions as an autocrine hormone, decreasing cell surface ferroportin, an iron exporter, increasing intracellular iron retention, and promoting prostate cancer cell survival. Synthesis of hepcidin in prostate cancer is controlled by a unique intersection of pathways that involves BMP4/7, IL6, Wnt, and the dual BMP and Wnt antagonist, SOSTDC1. Epigenetic silencing of SOSTDC1 through methylation is increased in prostate cancer and is associated with accelerated disease progression in patients with prostate cancer. These results establish a new connection between iron metabolism and prostate cancer, and suggest that prostatic dysregulation of hepcidin contributes to prostate cancer growth and progression. (C) 2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据